Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EPS (Basic) (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed EPS (Basic) for 5 consecutive years, with $0.19 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) rose 272.73% year-over-year to $0.19, compared with a TTM value of $0.8 through Dec 2025, up 233.33%, and an annual FY2025 reading of $0.8, up 233.33% over the prior year.
  • EPS (Basic) was $0.19 for Q4 2025 at Kiniksa Pharmaceuticals International, down from $0.25 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $3.23 in Q3 2022 and bottomed at -$0.72 in Q1 2021.
  • Average EPS (Basic) over 5 years is $0.04, with a median of -$0.14 recorded in 2023.
  • The sharpest move saw EPS (Basic) soared 817.78% in 2022, then plummeted 129.73% in 2024.
  • Year by year, EPS (Basic) stood at -$0.52 in 2021, then soared by 111.54% to $0.06 in 2022, then skyrocketed by 516.67% to $0.37 in 2023, then tumbled by 129.73% to -$0.11 in 2024, then surged by 272.73% to $0.19 in 2025.
  • Business Quant data shows EPS (Basic) for KNSA at $0.19 in Q4 2025, $0.25 in Q3 2025, and $0.24 in Q2 2025.